tradingkey.logo

Jupiter Neurosciences Inc

JUNS

1.500USD

+0.140+10.29%
Cierre 08/04, 16:00ETCotizaciones retrasadas 15 min
49.66MCap. mercado
PérdidaP/E TTM

Jupiter Neurosciences Inc

1.500

+0.140+10.29%
Más Datos de Jupiter Neurosciences Inc Compañía
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. It has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Información de la empresa
Símbolo de cotizaciónJUNS
Nombre de la empresaJupiter Neurosciences Inc
Fecha de salida a bolsaDec 03, 2024
Director ejecutivoMr. Christer Rosen
Número de empleados4
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 03
Dirección1001 North US HWY 1, Suite 504
CiudadPALM BEACH GARDENS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33477
Teléfono15614066154
Sitio Webhttps://jupiterneurosciences.com/
Símbolo de cotizaciónJUNS
Fecha de salida a bolsaDec 03, 2024
Director ejecutivoMr. Christer Rosen
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
11.55M
+0.03%
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
--
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
112.78K
+0.67%
Ms. Allison W. Brady
Ms. Allison W. Brady
Director
Director
21.75K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Director
Director
10.78K
--
Mr. Nicholas H. Hemmerly
Mr. Nicholas H. Hemmerly
Director
Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Julie Kampf
Ms. Julie Kampf
Director
Director
--
--
Dr. Marshall A Hayward, Ph.D.
Dr. Marshall A Hayward, Ph.D.
Co-Founder, Chief Scientific Officer, Director
Co-Founder, Chief Scientific Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
11.55M
+0.03%
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
--
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
112.78K
+0.67%
Ms. Allison W. Brady
Ms. Allison W. Brady
Director
Director
21.75K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Director
Director
10.78K
--
Mr. Nicholas H. Hemmerly
Mr. Nicholas H. Hemmerly
Director
Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 9 de jul
Actualizado: mié., 9 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Rosen (Christer)
34.90%
Wahlestedt (Claes M.D., Ph.D.)
8.47%
Hayward (Marshall A Ph.D.)
7.19%
Brothers (Shaun P.)
5.13%
Rosen (Alexander Gustaf Erik)
1.37%
Other
42.94%
Accionistas
Accionistas
Proporción
Rosen (Christer)
34.90%
Wahlestedt (Claes M.D., Ph.D.)
8.47%
Hayward (Marshall A Ph.D.)
7.19%
Brothers (Shaun P.)
5.13%
Rosen (Alexander Gustaf Erik)
1.37%
Other
42.94%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
57.70%
Investment Advisor
0.49%
Research Firm
0.34%
Hedge Fund
0.31%
Investment Advisor/Hedge Fund
0.03%
Other
41.13%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
18
19.49M
58.89%
+1.54M
2025Q1
16
18.33M
55.39%
+383.02K
2024Q4
9
17.92M
54.13%
+14.81M
2024Q3
6
5.31M
79.52%
--
2024Q2
10
5.31M
79.52%
-11.63K
2024Q1
10
5.31M
79.52%
-11.63K
2023Q4
10
5.31M
79.52%
-11.63K
2023Q3
10
5.31M
79.52%
-11.63K
2023Q2
10
5.31M
79.52%
-11.63K
2023Q1
11
5.31M
79.57%
-15.77K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Rosen (Christer)
11.55M
34.89%
+981.28K
+9.29%
Jun 30, 2025
Wahlestedt (Claes M.D., Ph.D.)
2.80M
8.47%
--
--
Mar 12, 2025
Hayward (Marshall A Ph.D.)
2.38M
7.19%
--
--
Mar 12, 2025
Brothers (Shaun P.)
1.70M
5.13%
--
--
Mar 12, 2025
Rosen (Alexander Gustaf Erik)
452.86K
1.37%
--
--
Mar 12, 2025
UBS Financial Services, Inc.
135.64K
0.41%
+135.62K
+542460.00%
Mar 31, 2025
Silva (Alison D)
112.03K
0.34%
+112.03K
--
Jun 30, 2025
Citi Investment Research (US)
111.98K
0.34%
+107.49K
+2393.92%
Mar 31, 2025
Two Sigma Investments, LP
90.19K
0.27%
+90.19K
--
Mar 31, 2025
Elmasri (Saleem C)
66.29K
0.2%
+66.29K
--
Jun 02, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI